Tsang, V.H.M., McGrath, R.T., Clifton-Bligh, R.J., Scolyer, R.A., Jakrot, V., Guminski, A.D., Long, G.V. and Menzies, A.M. (2019) Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 104, 5499-5506.
https://doi.org/10.1210/jc.2019-00423

has been cited by the following article:

• TITLE: Long-Term Persistent Absolute Insulin Secretion Deficiency in Diabetes Induced by Immune Checkpoint Inhibitors

  AUTHORS: Moctar Bah, Clara Bouché, Jean-François Gautier

  KEYWORDS: Immune Checkpoint Inhibitors, Nivolumab, Ipilimumab, Fulminant Diabetes, Insulin-Requiring Diabetes

  JOURNAL NAME: Open Journal of Endocrine and Metabolic Diseases, Vol.13 No.12, December 27, 2023

  ABSTRACT: Immune checkpoint inhibitors are today an immense hope in the management of cancers. However, since their widespread use, many cases of insulin-requiring diabetes appearing suddenly, as fulminant diabetes have been reported. Here, we describe 4 cases that occurred at different times after the beginning of immune checkpoint inhibitor therapy with Nivolumab alone or associated with Ipilimumab. There are 3 cases of newly diagnosed diabetes and 1 case of known type 2 diabetes formerly quite well balanced with Metformin. The clinical and biological characteristics of these patients are quite similar. They were all insulin-requiring at the discovery of diabetes and remained so throughout their follow-up. This type of diabetes which looks like type 1 diabetes seems rather to be a new entity.